Events

See more events

News

BVI Announces New York Eye and Ear Infirmary of Mount Sinai as First Institution in New York City and Tri-State Area to Adopt Leos – FDA-Cleared Laser Endoscopy System Offering a New Standard in Minimally Invasive Glaucoma Surgery

Posted on
  • BVI’s Leos system has been used clinically for the first time at New York Eye and Ear Infirmary, marking the first academic institution to acquire and utilize the system in the New York tri-state area.
  • Leos is the first and only FDA-cleared laser system with advanced digital endoscopic visualization for ab interno intraocular pressure reduction.

Read More

BVI Completes First U.S. Implantations of FDA-Approved FINEVISION® HP Trifocal IOL

Posted on
  • BVI announced the first successful U.S. implantations of its FDA-approved FINEVISION® HP trifocal IOL, marking the transition from regulatory clearance to real-world surgical use.
  • Five leading cataract and refractive surgeons performed the initial procedures, advancing BVI’s disciplined, surgeon-led rollout of a category-defining trifocal platform with more than 15 years of global clinical use and proven patient outcomes.

WALTHAM, Mass., February 10, 2026 — BVI, a global leader in ophthalmic device innovation, announced the first successful U.S. implantations of its FDA-approved FINEVISION HP hydrophobic trifocal intraocular lens (IOL), marking the long-anticipated arrival of one of the most established trifocal platforms in global cataract surgery and a major milestone following the product’s U.S. regulatory clearance in October 2025. Read More

BVI’s FINEVISION® HP Gains FDA Approval, Ushering in a New Era of Advanced Trifocal IOLs for U.S. Patients

Posted on
  • Milestone strengthens the company’s leadership in advanced IOL innovation
  • FINEVISION HP, with millions of implantations worldwide, will now be available to U.S. patients
  • Proprietary design features anchor the launch of BVI’s expanded U.S. IOL portfolio

WALTHAM, Mass., Oct. 14, 2025 — BVI, a global leader in ophthalmic device innovation, today announced that the U.S. Food and Drug Administration (FDA) has approved its FINEVISION HP trifocal intraocular lens (IOL). This milestone reinforces BVI’s leadership in premium IOLs and expands advanced vision solutions for U.S. patients. Read More

BVI Unveils Virtuoso® – A Novel Dual-Function Surgical Platform for Cataract and Vitreoretinal Procedures

Posted on
  • BVI announces Virtuoso®, its first dual-function phaco-vitrectomy system designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
  • European debut planned for 2025 Global ophthalmic congresses in Europe (Euretina and ESCRS).  

Waltham, Mass., September 3, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the European market unveiling of its innovative phaco-vitrectomy surgical platform, Virtuoso®, a dual-function system designed for both cataract and vitreoretinal procedures. Read More

See more news